Financial insights of ADIA

MyFinsight

For the quarter ending 2026-03-31, ADIA made $176,275 in revenue. -$162,525 in net income. Net profit margin of -92.20%.

Income Statement	2026-03-31	2025-12-31
Total revenue	176,275	175,127*
Total revenue-Supplements	-	323.75*
Supplements	0	-
Total revenue-Procedures	-	54,488.75*
Procedures	70,962	-
Total revenue-Biologics	-	72,397*
Biologics	37,736	-
Total cost of revenue	108,698	127,209.5*
Gross profit	67,577	47,917.5*
General and administrative	33,778	12,847.25*
Advertising and promotion	37,007	19,551.75*
Clinical trial fees	4,850	1,725*
Corporate filings	4,005	4,627.5*
Equipment leases	6,696	7,946*
Legal and professional fees	78,809	34,506.5*
Licenses	-	672*
Public relations	2,440	4,198.75*
Repairs and maintenance	1,010	1,321*
Research and development	-	7,286*
Rent	16,183	16,159*
Salaries and wages	32,602	15,441.75*
Shared-based compensation	-	10,562.5*
Utilities	866	1,585.75*
Depreciation and amortization	1,251	1,109.75*
Total operating expenses	219,497	139,540.5*
Loss from operations	-151,920	-91,623*
Interest income	375	156.25*
Sublease income	-	500*
Interest expense line of credit (related party)	10,980	7,899.25*
Total other income (expense)	-10,605	-7,243*
Net loss before provision for income taxes	-162,525	-98,866*
Provision for income taxes	0	0*
Net loss	-162,525	-98,866

Basic EPS	0	-0.001
Diluted EPS	0	-0.001
Basic Average Shares	94,404,696	93,596,730
Diluted Average Shares	94,404,696	93,596,730